The published results of the post-marketing ORAL Surveillance study, which compared the
Janus kinase (JAK) inhibitor tofacitinib with anti-TNF therapy in older patients with …

Currently, medications used to treat rheumatoid arthritis (RA) are glucocorticoids (GCs) and
nonsteroidal anti‐inflammatory drugs (NSAIDs), predominantly used for controlling the pain …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

Despite the medical advances and interventions to improve the quality of life of those in
intensive care, people with cancer or severely immunocompromised or other susceptible …

Invasive aspergillosis (IA) in haematology/oncology patients presents as primary infection or
breakthrough infection, which can become refractory to antifungal treatment and has a high …

6.1. Background The incidence of tuberculosis (TB) is a concern at the start of the third
millennium, particularly with the increase of multiresistant (MDR-TB) and extended resistant …

Summary Coronavirus disease 2019 (COVID-19) currently has few effective treatments.
Given the uncertainty surrounding the effectiveness and uptake of a vaccine, it is important …

Tumor necrosis factor (TNF)-α is a potent pro-inflammatory and pathological cytokines in
inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases. Anti …

Introduction: Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory
approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and …

An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous
Mycobacterial Diseases | American Journal of Respiratory and Critical Care Medicine ATS …